RAMM Pharma
A leader in the research and development of cannabinoid pharmaceutical formulations..
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | CAD46.7m | Post IPO Equity |
| Total Funding | 000k | ||
| CAD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (33 %) | (3 %) | (24 %) | (5 %) | 30 % | (14 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (3 %) | (37 %) | (125 %) | (154 %) | (169 %) | (103 %) | (127 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (8 %) | (122 %) | (136 %) | (173 %) | (538 %) | (152 %) | (380 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
RAMM Pharma Corp. is a pharmaceutical and medical products company with a focus on cannabinoid pharmacology and the formulation of cannabis-based pharmaceuticals. Founded in 1988 in Montevideo, Uruguay, the company has established itself in the pharmaceutical sector, later expanding its focus to include plant-derived cannabinoid products. The company is headquartered in Toronto, Canada, and its operations span across Uruguay, Italy, and Poland.
The business is structured around the development, production, and sale of cannabinoid pharmaceutical formulations, cosmetics, and nutraceutical products. Revenue is generated from the sales of these products, as well as from medical devices and consumables. RAMM Pharma's business model is built on vertical integration, controlling the process from cultivation to the final product, which allows for supply chain control and potential economies of scale. The company serves markets in Latin America and Europe, with a significant portion of its revenue derived from Uruguay.
RAMM Pharma’s product portfolio includes medically registered and approved plant-derived cannabinoid pharmaceuticals. One of its key products is Epifractán, a cannabinoid-based pharmaceutical drug. Another offering is CannabiPiel, a cosmeceutical product aimed at treating chronic pain and inflammation. The company also has a line of hemp-based nutrition and specialized veterinary products in its development pipeline. These products are manufactured in a Good Manufacturing Practice (GMP) certified facility in Montevideo. The company has engaged in strategic acquisitions, such as Canapar Corp., a European cannabis company, to enhance its vertical integration and expand its footprint in the European market. RAMM Pharma Corp. is publicly traded on the Canadian Securities Exchange under the ticker RAMM.
Keywords: cannabinoid pharmaceuticals, medical cannabis, pharmaceutical manufacturing, cosmeceuticals, nutraceuticals, vertical integration, plant-derived medicine, GMP certified, Latin America pharmaceuticals, European cannabis market, Epifractán, CannabiPiel, veterinary cannabinoid products, pharmaceutical sales, medical consumables, public company, CSE:RAMM, Canapar, HemPoland, cannabis cultivation, drug formulation, international sales
